ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos1.61 B1.6 B1.72 B1.74 B1.83 B1.78 B7.07 BInvestigación y desarrollo459 M443 M526 M514 M569 M516 M2.13 BBeneficio operativo675 M921 M819 M1.05 B825 M1.1 B3.79 BTotal de ingresos no operativos-115 M-144 M341 M-120 M-173 M219 M267 MGastos por intereses, netos de intereses capitalizados80 M82 M90 M87 M90 M90 M357 MIngresos no operativos, una vez deducidos los gastos por intereses-106 M-110 M129 M-97 M-139 M68 M-39 MIngresos/gastos extraordinarios-89 M-116 M122 M-110 M-124 M61 M-51 MBeneficio antes de impuestos585 M805 M941 M939 M700 M1.16 B3.74 BParticipación en los beneficios———————Impuestos23 M133 M146 M183 M31 M-176 M184 MParticipación minoritaria-5 M-2 M-2 M0-2 M-2 M-6 MOtros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas563 M672 M795 M755 M670 M1.34 B3.56 BOperaciones suspendidas———————Beneficio neto563 M672 M795 M755 M670 M1.34 B3.56 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas565 M674 M797 M755 M672 M1.34 B3.56 BBeneficio básico por acción0.380.460.540.510.450.92.4Beneficio por acción diluido0.380.450.530.510.450.92.39Número medio de acciones ordinarias1.47 B1.48 B1.48 B1.48 B1.48 B1.48 B—Acciones diluidas1.49 B1.49 B1.49 B1.5 B1.49 B1.5 B—EBITDA1.02 B1.25 B1.16 B1.39 B1.19 B1.45 B5.18 BEBIT676 M922 M819 M1.05 B823 M1.1 B3.79 BCosto de los ingresos1.47 B1.45 B1.64 B1.52 B1.61 B1.59 B6.36 BOtros costes de producción———————Amortización y depreciación (flujo de caja)348 M325 M336 M342 M365 M351 M1.39 B
Boston Scientific Corporation Common Stock
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.